Tags

Type your tag names separated by a space and hit enter

Neuromyelitis Optica-AQP4: an update.
Curr Rheumatol Rep 2011; 13(6):496-505CR

Abstract

Devic disease (neuromyelitis optica [NMO]) is an idiopathic inflammatory demyelinating and necrotizing disease characterized by optic neuritis and transverse myelitis, either simultaneously or in isolation. NMO is often idiopathic but may also be associated with systemic autoimmune disease. The prognosis of NMO is severe, especially in those with early and recurrent relapses. MRI studies have revealed that most frequently, there is a long spinal cord lesion that extends through three or more vertebral segments in length. NMO-IgG is the first antibody marker for any inflammatory central nervous system disorder and is both sensitive and specific for NMO. The identification of NMO-IgG in patients with recurrent optic neuritis or longitudinally extensive myelitis and its ability to predict subsequent relapse support the concept of a spectrum of NMO disorders. Treatment in the acute phase includes intravenous steroids and plasma exchange therapy. Immunosuppressive agents are recommended for the prophylaxis of relapses.

Authors+Show Affiliations

Rheumatology Section, Hospital Cullen, Santa Fé, Argentina. litobenavente@yahoo.com.arNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21922173

Citation

Benavente, Emilio, and Sergio Paira. "Neuromyelitis Optica-AQP4: an Update." Current Rheumatology Reports, vol. 13, no. 6, 2011, pp. 496-505.
Benavente E, Paira S. Neuromyelitis Optica-AQP4: an update. Curr Rheumatol Rep. 2011;13(6):496-505.
Benavente, E., & Paira, S. (2011). Neuromyelitis Optica-AQP4: an update. Current Rheumatology Reports, 13(6), pp. 496-505. doi:10.1007/s11926-011-0211-9.
Benavente E, Paira S. Neuromyelitis Optica-AQP4: an Update. Curr Rheumatol Rep. 2011;13(6):496-505. PubMed PMID: 21922173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuromyelitis Optica-AQP4: an update. AU - Benavente,Emilio, AU - Paira,Sergio, PY - 2011/9/17/entrez PY - 2011/9/17/pubmed PY - 2012/3/1/medline SP - 496 EP - 505 JF - Current rheumatology reports JO - Curr Rheumatol Rep VL - 13 IS - 6 N2 - Devic disease (neuromyelitis optica [NMO]) is an idiopathic inflammatory demyelinating and necrotizing disease characterized by optic neuritis and transverse myelitis, either simultaneously or in isolation. NMO is often idiopathic but may also be associated with systemic autoimmune disease. The prognosis of NMO is severe, especially in those with early and recurrent relapses. MRI studies have revealed that most frequently, there is a long spinal cord lesion that extends through three or more vertebral segments in length. NMO-IgG is the first antibody marker for any inflammatory central nervous system disorder and is both sensitive and specific for NMO. The identification of NMO-IgG in patients with recurrent optic neuritis or longitudinally extensive myelitis and its ability to predict subsequent relapse support the concept of a spectrum of NMO disorders. Treatment in the acute phase includes intravenous steroids and plasma exchange therapy. Immunosuppressive agents are recommended for the prophylaxis of relapses. SN - 1534-6307 UR - https://www.unboundmedicine.com/medline/citation/21922173/Neuromyelitis_Optica_AQP4:_an_update_ L2 - https://dx.doi.org/10.1007/s11926-011-0211-9 DB - PRIME DP - Unbound Medicine ER -